2.30Open2.30Pre Close0 Volume2 Open Interest75.00Strike Price0.00Turnover279.34%IV70.31%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry2.30Extrinsic Value100Contract SizeAmericanOptions Type-0.0249Delta0.0003Gamma106.47Leverage Ratio-0.2007Theta-0.0053Rho-2.65Eff Leverage0.0382Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet